The company has demonstrably boosted the development of the new treatment for cardiac amyloidosis, leveraging the compound. Initial clinical information indicates promising outcomes for individuals affected by this https://bridgebio740341.blogolize.com/bridgebio-progresses-attr-cm-management-through-the-drug-81337231